Shareholders to Vote on 7% Potential Dilution for Incentive Plan; CEO Compensation Exceeds $32M

summarizeSummary

Bausch & Lomb is seeking shareholder approval for a 25 million share increase in its incentive plan, representing approximately 7% potential dilution, while disclosing CEO compensation over $32 million and a significant modification to his equity awards.

check_boxKey Events

• Proposed Share Pool Increase

  Shareholders will vote on Proposal 3 to amend and restate the 2022 Omnibus Incentive Plan, increasing the authorized shares for issuance by an additional 25,000,000 common shares. This represents approximately 7% potential dilution based on current outstanding shares.

• CEO Compensation and Equity Modification

  CEO Brenton L. Saunders' total compensation for 2025 was $32,194,326. His New Hire PSUs were modified in 2025, resulting in an incremental fair value of $12,862,500, to ensure continued employment terms are not contingent on the BHC spin-off and to adjust performance metrics.

• Board Refreshment

  Two new independent directors, Dr. Eduardo Alfonso and Mr. Steven H. Collis, were appointed effective January 1, 2026, replacing Messrs. Icahn and Hu who resigned in 2025. The board is now 90% independent.

• Annual Shareholder Meeting Scheduled

  The 2026 Annual Meeting of Shareholders will be held virtually on Wednesday, May 20, 2026, at 10:30 a.m. Eastern Daylight Time, where shareholders will vote on the proposals.

auto_awesomeAnalysis

Bausch & Lomb's definitive proxy statement outlines key proposals for its upcoming annual meeting, most notably a request for shareholder approval to increase the Omnibus Incentive Plan's share reserve by 25 million common shares. This represents a significant potential dilution of approximately 7% of current outstanding shares, which could impact shareholder value. Additionally, the filing details substantial executive compensation, with CEO Brenton L. Saunders' total compensation for 2025 exceeding $32 million. A notable modification to his New Hire PSUs, valued at an incremental $12.86 million, was made to ensure executive retention and align incentives with long-term performance, independent of the Bausch Health Companies Inc. spin-off timing. Investors should carefully consider the dilutive impact of the proposed share increase and the structure of executive compensation.